Astal Laboratories Files Statement of Fund Utilization for Q3 FY26 with BSE
Published on: Feb. 15, 2026, 12:50 a.m. | Source: scanx.trade
Astal Laboratories Limited filed its Q3 FY26 Statement of Deviation and Variation with BSE, reporting no deviations in fund utilization. The company raised Rs. 281.98 lakhs through preferential allotment on 12-08-2025 and has utilized Rs. 218.10 lakhs for capital expenditure, working capital, and general corporate purposes as originally planned. The Audit Committee and auditors provided no adverse comments on the fund deployment.
